Relx Plc (NYSE:RELX) Shares Acquired by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC increased its stake in Relx Plc by 0.5% during Q1, now holding over 1.2 million shares valued at approximately $60.9 million.
• Relx announced a semi-annual dividend of $0.2634 per share, resulting in a yield of 1.7%, with the ex-dividend date set for August 8th.
• Analysts have generally rated Relx as a "Buy," with upgrades from several brokerages, though the stock recently fell by 0.3% to $51.76.

Natixis Advisors LLC lifted its stake in shares of Relx Plc (NYSE:RELX - Free Report) by 0.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,208,467 shares of the technology company's stock after buying an additional 5,875 shares during the quarter. Natixis Advisors LLC owned about 0.07% of Relx worth $60,919,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its holdings in shares of Relx by 612.5% in the 1st quarter. Larson Financial Group LLC now owns 513 shares of the technology company's stock worth $26,000 after acquiring an additional 441 shares during the period. Golden State Wealth Management LLC boosted its position in Relx by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 588 shares of the technology company's stock worth $30,000 after purchasing an additional 294 shares in the last quarter. Cornerstone Planning Group LLC grew its holdings in Relx by 325.2% in the first quarter. Cornerstone Planning Group LLC now owns 693 shares of the technology company's stock valued at $37,000 after purchasing an additional 530 shares during the last quarter. Transce3nd LLC acquired a new stake in Relx in the fourth quarter valued at $40,000. Finally, Brown Brothers Harriman & Co. increased its position in shares of Relx by 218.5% in the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company's stock valued at $44,000 after buying an additional 662 shares in the last quarter. Institutional investors and hedge funds own 15.02% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Wall Street Zen upgraded Relx from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Morgan Stanley reissued an "overweight" rating on shares of Relx in a report on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Relx currently has an average rating of "Buy".

Relx Trading Up 0.2%

Shares of NYSE:RELX traded up $0.13 during trading on Monday, reaching $51.72. The stock had a trading volume of 515,853 shares, compared to its average volume of 795,122. The company has a quick ratio of 0.42, a current ratio of 0.47 and a debt-to-equity ratio of 2.55. The stock has a market cap of $94.99 billion, a P/E ratio of 27.81, a PEG ratio of 3.36 and a beta of 0.88. The business has a fifty day moving average price of $53.31 and a 200-day moving average price of $51.59. Relx Plc has a fifty-two week low of $43.45 and a fifty-two week high of $56.33.

Relx Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, September 16th. Stockholders of record on Friday, August 8th will be issued a dividend of $0.2634 per share. The ex-dividend date is Friday, August 8th. This represents a dividend yield of 170.0%. Relx's payout ratio is presently 65.05%.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.